Cargando…

Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy

Multiple myeloma (MM) is a plasma cell dyscrasia characterized by the clonal proliferation of antibody producing plasma cells. Despite the use of next generation proteasome inhibitors (PI), immunomodulatory agents (IMiDs) and immunotherapy, the development of therapy refractory disease is common, wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nair, Remya, Gupta, Pulkit, Shanmugam, Mala
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523312/ https://www.ncbi.nlm.nih.gov/pubmed/36185202 http://dx.doi.org/10.3389/fonc.2022.1000106

Ejemplares similares

Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma
por: Sharma, Aditi, et al.
Publicado: (2022)

The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma
por: Findlay, Steven, et al.
Publicado: (2023)

β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma
por: Nair, Remya, et al.
Publicado: (2022)

Acupuncture Synergized With Bortezomib Improves Survival of Multiple Myeloma Mice via Decreasing Metabolic Ornithine
por: Ke, Mengying, et al.
Publicado: (2021)

Current Role of Radiation Therapy for Multiple Myeloma
por: Talamo, Giampaolo, et al.
Publicado: (2015)

Editorial: T-cell directed therapies in multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2023)

Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma
por: Slomp, Anne, et al.
Publicado: (2018)

Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment
por: Matamala Montoya, María, et al.
Publicado: (2023)

Shutting off the fuel supply to target metabolic vulnerabilities in multiple myeloma
por: Rana, Priyanka S., et al.
Publicado: (2023)

Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
por: Chen, Ying, et al.
Publicado: (2020)

Local Radiation Therapy for Palliation in Patients With Multiple Myeloma of the Spine
por: Mark, Daniel, et al.
Publicado: (2019)

Preclinical evidence of a direct pro-survival role of arginine deprivation in multiple myeloma
por: Trudu, Matteo, et al.
Publicado: (2022)

Metabolic Reprogramming Induces Immune Cell Dysfunction in the Tumor Microenvironment of Multiple Myeloma
por: Wu, Shaojie, et al.
Publicado: (2021)

Targeting the Endothelin-1 Receptors Curtails Tumor Growth and Angiogenesis in Multiple Myeloma
por: Russignan, Anna, et al.
Publicado: (2021)

Corrigendum: Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
por: Chen, Ying, et al.
Publicado: (2021)

Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy
por: Schinke, Carolina, et al.
Publicado: (2023)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

MRI-Based Bone Marrow Radiomics Nomogram for Prediction of Overall Survival in Patients With Multiple Myeloma
por: Li, Yang, et al.
Publicado: (2021)

Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors
por: Schwestermann, Jonas, et al.
Publicado: (2022)

The Role of Clonal Evolution on Progression, Blood Parameters, and Response to Therapy in Multiple Myeloma
por: Sandmann, Sarah, et al.
Publicado: (2022)

Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
por: Vu, Son Hai, et al.
Publicado: (2023)

Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients
por: Zheng, Gaofeng, et al.
Publicado: (2022)

Management of Multiple Myeloma and Usage of Bortezomib: Perspective from India and Ukraine
por: Garg, Amit, et al.
Publicado: (2016)

Editorial: Molecular Mechanisms of Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Glutamine Transport and Mitochondrial Metabolism in Cancer Cell Growth
por: Scalise, Mariafrancesca, et al.
Publicado: (2017)

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
por: Cornell, Robert Frank, et al.
Publicado: (2019)

Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival
por: Herrero, Ana Belén, et al.
Publicado: (2017)

High Efficacy of Stem Cell Mobilization With Etoposide+Cytarabine Plus G-CSF in Patients With Multiple Myeloma
por: Zhu, Zhijuan, et al.
Publicado: (2022)

Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
por: Mian, Hira, et al.
Publicado: (2022)

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Association between metabolic obesity phenotypes and multiple myeloma hospitalization burden: A national retrospective study
por: Zhang, Yue, et al.
Publicado: (2023)

An Uncommon Cause of Acute Encephalopathy in Multiple Myeloma
por: Al Zeyoudi, Jawaher, et al.
Publicado: (2021)

PET/CT in Multiple Myeloma: Beyond FDG
por: Matteucci, Federica, et al.
Publicado: (2021)

The Apparent Diffusion Coefficient of Diffusion-Weighted Whole-Body Magnetic Resonance Imaging Affects the Survival of Multiple Myeloma Independently
por: Zhang, Bei, et al.
Publicado: (2022)

Socioeconomic status-based survival disparities and nomogram prediction for patients with multiple myeloma: Results from American and Chinese populations
por: Xu, Jiaxuan, et al.
Publicado: (2022)

Machine Learning–Based Overall Survival Prediction of Elderly Patients With Multiple Myeloma From Multicentre Real-Life Data
por: Bao, Li, et al.
Publicado: (2022)

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma
por: Domenger, Antoine, et al.
Publicado: (2023)

Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience
por: Iula, Rossella, et al.
Publicado: (2022)

PIWIL1 Drives Chemoresistance in Multiple Myeloma by Modulating Mitophagy and the Myeloma Stem Cell Population
por: Wang, Yajun, et al.
Publicado: (2022)

Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities
por: Jia, Shuangshuang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i52bl01s7kc8nk8f8bdelgc2s7